<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04658407</url>
  </required_header>
  <id_info>
    <org_study_id>AP-HP200240</org_study_id>
    <nct_id>NCT04658407</nct_id>
  </id_info>
  <brief_title>Patients' Outcome With Severe or Fulminant Hepatic Insufficiency, Hospitalized in the Public Hospitals of Paris</brief_title>
  <acronym>DEVINHEF</acronym>
  <official_title>Patients' Outcome With Severe or Fulminant Hepatic Insufficiency, Hospitalized in the Hospitals of the Assistance Publique - Hôpitaux de Paris (APHP)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective is to determine the medical fate (transplanted or not and living or&#xD;
      deceased), of patients with Severe, fulminating acute liver failure in the public hospitals&#xD;
      of paris.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Severe, fulminating acute liver failure is a rare but serious disease. The overall prognosis&#xD;
      has improved in recent years thanks to advances in medical management and liver&#xD;
      transplantation.&#xD;
&#xD;
      However, the epidemiology of this disease in France, the survival with or without liver&#xD;
      transplantation of these patients and the factors that can influence this survival are not&#xD;
      well known.&#xD;
&#xD;
      The main objective is to determine the medical fate (transplanted or not and living or&#xD;
      deceased), of patients with Severe, fulminating acute liver failure in the public hospitals&#xD;
      of paris (APHP).&#xD;
&#xD;
      The data will come from the APHP Health Data Warehouse&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 1, 2021</start_date>
  <completion_date type="Anticipated">December 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The main objective is to determine the medical fate (transplanted or not and living or deceased), of patients with Severe and fulminating acute hepatic failure within AP-HP hospitals</measure>
    <time_frame>1 month from the diagnosis of this episode</time_frame>
    <description>Patient status 1 month after diagnosis of this episode (alive or dead with or without transplantation)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Epidemiology of Severe and fulminating acute hepatic failure</measure>
    <time_frame>Baseline</time_frame>
    <description>Sex Ratio M / F and cause of liver failure</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cause of death</measure>
    <time_frame>From date of inclusion until the date of death from any cause, assessed up to 9 years</time_frame>
    <description>Cause of death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Analysis of Clinical Pathway</measure>
    <time_frame>up to 1month after the diagnosis of this episode</time_frame>
    <description>Identification of the different services visited</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Reasons for new hospitalizations with an admission date within 6 months after the diagnosis this episode</measure>
    <time_frame>within 6 months after the diagnosis this episode</time_frame>
    <description>Identification by the usual code of the new hospitalization, consecutive to the episode</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">18000</enrollment>
  <condition>Fulminating Hepatic Failure</condition>
  <arm_group>
    <arm_group_label>all patients diagnosed with a severe hepatic failure</arm_group_label>
    <description>Retrospective cohort using only data already entered in the Health data warehouse of the APHP (Public Paris Hospital)</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Patient with Severe liver failure or toxicants that may cause a liver failure&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 15&#xD;
&#xD;
          -  Severe liver failure or toxicants that may cause a liver failure Or&#xD;
&#xD;
          -  (PR&lt;50% or INR &gt;1.5) And ALT &gt;250&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with underlying chronic liver disease&#xD;
&#xD;
          -  Patients with the conditions given by this following ICD (International Classification&#xD;
             of Diseases) : B18 - E831 - K70 - K715 - K717 - K730- K731 - K732 - 738 - K74 - K753 -&#xD;
             K758 - K760 - K761&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>15 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Philippe ICHAI</last_name>
    <phone>01 45 59 64 35</phone>
    <email>philippe.ichai@aphp.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Paul Brousse Hospital</name>
      <address>
        <city>Villejuif</city>
        <zip>94804</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Philippe ICHAI, MD, PhD</last_name>
      <phone>+33 (1) 45 59 64 35</phone>
      <email>philippe.ichai@aphp.fr</email>
    </contact>
    <investigator>
      <last_name>Philippe ICAHI, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>September 21, 2020</study_first_submitted>
  <study_first_submitted_qc>December 7, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">December 8, 2020</study_first_posted>
  <last_update_submitted>February 26, 2021</last_update_submitted>
  <last_update_submitted_qc>February 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatic Insufficiency</mesh_term>
    <mesh_term>Liver Failure</mesh_term>
    <mesh_term>Liver Failure, Acute</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

